Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Concepts for agonistic targeting of CD40 in immuno-oncology.
Richards DM, Sefrin JP, Gieffers C, Hill O, Merz C. Richards DM, et al. Hum Vaccin Immunother. 2020;16(2):377-387. doi: 10.1080/21645515.2019.1653744. Epub 2019 Sep 5. Hum Vaccin Immunother. 2020. PMID: 31403344 Free PMC article. Review.
Critically, receptor assembly into functional trimeric signaling complexes occurs through binding of the natural ligand unit. TNF-R-SF members, including CD40, have been key immunotherapeutic targets for over 20 years. ...In this review, we describe the biology and …
Critically, receptor assembly into functional trimeric signaling complexes occurs through binding of the natural ligand unit. TNF-R-SF membe …
A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation.
Mega A, Mebrahtu A, Aniander G, Ryer E, Sköld A, Sandegren A, Backström Rydin E, Rockberg J, Östman A, Frejd FY. Mega A, et al. MAbs. 2023 Jan-Dec;15(1):2223750. doi: 10.1080/19420862.2023.2223750. MAbs. 2023. PMID: 37332119 Free PMC article.
A novel PDGFRBxCD40 Fc-silenced bispecific AffiMab was developed to this end to test whether it is possible to activate CD40 in a PDGFRB-targeted manner. A PDGFRB-binding Affibody molecule was fused to each heavy chain of an Fc-silenced CD40 agonistic
A novel PDGFRBxCD40 Fc-silenced bispecific AffiMab was developed to this end to test whether it is possible to activate CD40 in a PDG …